Vertaling van "row the number of " (Nederlands → Frans) :

Veterinary medicines Unit For the fifth year in a row the number of applications closed for obtaining marketing authorisation (MA) within the Veterinary medicines Unit has exceeded the number of new applications submitted.
Veterinary medicines Unit For the fifth year in a row the number of applications closed for obtaining marketing authorisation (MA) within the Veterinary medicines Unit has exceeded the number of new applications submitted.

Recent onderzoek (Liddle en Rowe, 1998; Hogue et al, 1998; Williams en Chang, 2000; Diamond en Diamond, 2001) heeft de volgende resultaten opgeleverd:
Les études récentes (Liddle et Rowe, 1998; Hogue et al, 1998; Williams et Chang, 2000; Diamond et Diamond, 2001) apportent les éléments suivants :

Bestand EMPLOPER Velden: CODE_AGR, YEAR_REGISTR, PERIOD_REGISTR, CODE_CAMPUS, CODE_UNIT, QUARTER_REGISTR, P1_Q_OR_F, P1_NUMBER_FTE_PAYED, P1_NUMBER_FTE_38_WEEK en P1_NUMBER_PERSONS
Fichier EMPLOPER Champs : CODE_AGR, YEAR_REGISTR, PERIOD_REGISTR, CODE_CAMPUS, CODE_UNIT, QUARTER_REGISTR, P1_Q_OR_F, P1_NUMBER_FTE_PAYED, P1_NUMBER_FTE_38_WEEK et P1_NUMBER_PERSONS

Bestand EMPLOPER Velden: CODE_AGR, YEAR_REGISTR, PERIOD_REGISTR, CODE_CAMPUS, CODE_UNIT, QUARTER_REGISTR, P1_Q_OR_F, P1_CODE_QUAL_FUNCTION, P1_NUMBER_FTE_PAYED, P1_NUMBER_FTE_38_WEEK en P1_NUMBER_PERSONS
Fichier EMPLOPER Champs : CODE_AGR, YEAR_REGISTR, PERIOD_REGISTR, CODE_CAMPUS, CODE_UNIT, QUARTER_REGISTR, P1_Q_OR_F, P1_CODE_QUAL_FUNCTION, P1_NUMBER_FTE_PAYED, P1_NUMBER_FTE_38_WEEK et P1_NUMBER_PERSONS

However, the figures do clearly show that there is a considerable number of early phase trials. There are 7 units in Belgium actively undertaking phase I clinical trials and a number of early phase trials are being conducted in centres where there is expertise in specific clinical areas.
However, the figures do clearly show that there is a considerable number of early phase trials. There are 7 units in Belgium actively undertaking phase I clinical trials and a number of early phase trials are being conducted in centres where there is expertise in specific clinical areas.

In 2008, there was a significant increase observed in the number of applications for clinical trials and amendments (changes to an existing file) and of the percentage of phase I trials. The absolute number of non-commercial (“academic”) trials remained stable.
In 2008, there was a significant increase observed in the number of applications for clinical trials and amendments (changes to an existing file) and of the percentage of phase I trials. The absolute number of non-commercial (“academic”) trials remained stable.

National representation A number of FAMHP employees represent the Minister of Public Health on a number of commissions and consultation platforms, such as the commission for the reimbursement of medicines (CTG - CRM) and the technical pharmaceutical board (TFR - CTP) of the RIZIV - INAMI, the price commission for pharmaceutical proprietary products of the FPS Economy, and of the FANC.
National representation A number of FAMHP employees represent the Minister of Public Health on a number of commissions and consultation platforms, such as the commission for the reimbursement of medicines (CTG - CRM) and the technical pharmaceutical board (TFR - CTP) of the RIZIV - INAMI, the price commission for pharmaceutical proprietary products of the FPS Economy, and of the FANC.

Commission for the establishment of retail pharmacies; French language chamber Total number of applications Total number of decisions
Commission for the establishment of retail pharmacies; French language chamber Total number of applications Total number of decisions

Some achievements and figures for the Veterinary Medicines unit in 2007 KPIs and measurement results The most important KPI for this unit is the proportion of the number of finalised applications to the number of new, submitted applications, as a measure of the evolution of the unit’s backlog.
Some achievements and figures for the Veterinary Medicines unit in 2007 KPIs and measurement results The most important KPI for this unit is the proportion of the number of finalised applications to the number of new, submitted applications, as a measure of the evolution of the unit’s backlog.

One striking point is the clear trend towards an increasing number of phase I trials, from 17% in 2004 to 24% in 2007, as well as the increase in the number of submitted academic clinical trials: from 3% in 2004 to 7% in 2007.
One striking point is the clear trend towards an increasing number of phase I trials, from 17% in 2004 to 24% in 2007, as well as the increase in the number of submitted academic clinical trials: from 3% in 2004 to 7% in 2007.